Hot Features
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-ki... OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.36 | 8.73786407767 | 4.12 | 4.545 | 4.015 | 212254 | 4.24635647 | CS |
| 4 | 0.88 | 24.4444444444 | 3.6 | 4.6 | 3.58 | 320538 | 4.23794311 | CS |
| 12 | 0.48 | 12 | 4 | 5.38 | 2.9 | 349258 | 4.14627937 | CS |
| 26 | 1.51 | 50.8417508418 | 2.97 | 5.38 | 2.23 | 230134 | 3.85992358 | CS |
| 52 | 2.08 | 86.6666666667 | 2.4 | 5.38 | 1.91 | 169266 | 3.51646594 | CS |
| 156 | -13.92 | -75.652173913 | 18.4 | 19.9992 | 1.7 | 145060 | 4.39607969 | CS |
| 260 | -13.92 | -75.652173913 | 18.4 | 19.9992 | 1.7 | 145060 | 4.39607969 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.